Does Trazodone Affect Sex Drive? What the Studies Actually Show

Trazodone and sex drive is really two questions that the internet has merged into one, and they do not get the same answer. On the lowering side, in the one head-to-head trial of three antidepressants in 195 people, single-blind, trazodone had the least desire impairment, well below sertraline and fluoxetine. The 2009 meta-analysis did not rank it at all. On the raising side, the "trazodone for erection problems" idea was tested through the 1990s and a 2003 meta-analysis found no significant benefit. The evidence that it rescues desire lost to an SSRI in women is one small open-label study, and the 2020 review's tiny-dose proposal is a receptor-modelling argument with no trial behind it. Priapism is a known rare risk of trazodone, and no rate for it appears in these studies.

Figures from Khazaie et al. 2015 (PMID 25467077) and Fink et al. 2003 (PMID 12930437).

Is it the trazodone, or is it me?

The internet has welded two separate questions together, and most of what you have read about trazodone and sex drive is answering both at once. So before anything else, figure out which one you are asking. If you were prescribed a low dose of trazodone for sleep and your drive has gone quiet, you are asking the first question: is this medicine doing it to you? That is a fair thing to wonder, because trazodone is sedating by design, and a lot of people on it are tired all the time. Low desire and constant fatigue travel together, and sleep, libido and testosterone covers how much broken sleep alone can explain. If you also wake up gasping or find yourself snoring heavily, sleep apnea and low libido is worth reading, because untreated apnea drains energy and hormone levels on its own.

If you are on trazodone for depression, the flatness may be the condition, the medication, or both. Depression and low libido goes through how much of the drop belongs to the illness itself. And if you read online that trazodone raises desire or fixes erection problems, you are asking the second question, which is a different animal entirely. The honest version of that story is thinner than the forum posts suggest, and the next sections walk through exactly what the trials showed, drug by drug, claim by claim.

Question one: does trazodone lower sex drive?

The cleanest answer comes from Khazaie and colleagues (2015), a single-blind randomized trial. 195 people with major depression, 102 men and 93 women, were allocated to fluoxetine (n=64), sertraline (n=67) or trazodone (n=64) for 14 weeks, with sexual function measured using the SFQ questionnaire. At baseline there was no significant difference between the groups. After treatment, the pattern split sharply. Fluoxetine showed the most impairment on desire items: 43% to 51% of men and 44% to 50% of women. Trazodone showed the least: 12% to 18% of men and 23% to 24% of women. Sertraline sat in between at 39% to 42%. Trazodone also had the lowest impairment on finishing-phase items in men, 9% to 15%. The caveats matter: the trial was single-blind, the data came from self-reported questionnaires, and the run was 14 weeks. The published summary gives no drug doses, no p values and no confidence intervals, so the gaps between the bars are clear in direction and unquantified in strength.

Serretti and colleagues (2009) took a wider net. Their meta-analysis pooled studies in which sexual function was deliberately assessed in people without prior sexual side effects, looking at treatment-emergent effects, overall and by specific phase. For ten drugs, those effects ran significantly higher than placebo, in decreasing order of impact: sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram and fluvoxamine, with sexual side effects in 25.8% to 80.3% of people. Six others showed no significant difference from placebo: agomelatine, amineptine, bupropion, moclobemide, mirtazapine and nefazodone. Trazodone appears in neither list. That is an absence of data. The honest read is that the pooled evidence simply did not rank it. The caveats are real: open-label studies were included and the scales used to assess sexual function varied across studies. The published summary gives no number of studies or people pooled, no confidence interval, no odds ratio and no I-squared. If you are on an SSRI and feeling the hit, our guide to SSRIs and the libido drop goes through what the bigger picture looks like.

Question two: the "trazodone brings it back" story

This is where the forum posts live, and where the evidence thins out fast. Fink and colleagues (2003) ran the systematic review and meta-analysis: six randomized trials of trazodone versus a control in men with erection problems, each running at least 7 days, 396 men in total. Three of the six showed an apparent clinically meaningful benefit over placebo, and that benefit was significant in two. Pooled, trazodone monotherapy produced a "positive treatment response" more often than placebo, 37% versus 20%, a relative benefit increase of 1.6, but the 95% confidence interval ran from 0.8 to 3.3, crossing the line of no difference, so the pooled result was not significant. Subgroup analyses suggested men with psychogenic problems might benefit more than those with mixed or physical causes, and efficacy appeared higher at higher doses, 150 to 200 versus 50 milligrams a day. Withdrawals were not significantly more frequent on trazodone; dry mouth hit 19%, sedation 16%, dizziness 16% and fatigue 15%. The caveats stack up: heterogeneous populations, small and brief trials, some methodologically weak, and wide confidence intervals. The review gives no priapism rate. None of the studies in this article do.

The individual trials behind that pool tell the same story. Costabile and colleagues (1999) ran a double-blind, placebo-controlled, fixed-dose crossover trial: 51 men with at least 3 months of complete erection problems, 50 milligrams trazodone or placebo at bedtime, crossed over after a 3-week washout, 48 completing both phases, mean age 65. Improved erections: 19% on trazodone versus 24% on placebo. Improved sex drive: 35% versus 20%. Mean index of sexual satisfaction: 31.7 to 27.5 on trazodone, 28.5 to 30.8 on placebo. Every comparison was non-significant. Side effects: drowsiness 31%, dry mouth 1%, fatigue 19%. The paper notes that prior studies cited had reported nearly 70% efficacy, all anecdotal, retrospective or in combination with yohimbine. Enzlin and colleagues (2000) added 34 men with erection problems without major organic findings, trazodone 200 milligrams a day versus placebo over a single 4-week phase. No significant differences in total erection duration, change in sexual desire, morning erections report, or the psychometric scales, and half the participants were non-compliant, which matters a lot in a trial this size.

Then come the two traps. Montorsi and colleagues (1994): 63 men with pure psychogenic erection problems received yohimbine 15 milligrams a day plus trazodone 50 milligrams a day, used together, versus placebo; 55 (87%) completed. A positive clinical outcome in 39 (71%), significantly better than placebo. The trap to state plainly: it was a combination, so the effect cannot be attributed to trazodone alone. Aydin and colleagues (1996): 79 men with no detectable organic cause, four arms: testosterone 20, trazodone 21, hypnotic suggestion 20, controls 18. Improvement in sexual function ran 39% in the control group, with the treated groups higher but not significantly so; success rates were 60% for testosterone, 67% for trazodone and 80% for hypnotic suggestion. The only treatment that appeared superior to placebo was hypnosis, and the report gives no p values or confidence intervals. If you want a cleaner look at a drug with actual trial-level sex-drive data, what the bupropion trials show is the place to go.

The women's study everyone quotes

One small study carries almost the entire "trazodone rescues desire lost to an SSRI" story, and it is worth knowing exactly how small. Stryjer and colleagues (2009) ran a preliminary open-label study: 20 people with SSRI-induced sexual side effects, 11 men and 9 women, and the authors note that up to 70% of people on SSRIs report such effects. Trazodone was added to the existing SSRI for 4 weeks, starting at 50 milligrams in week one and rising to 100 milligrams; 15 completed. The primary outcome covered four dimensions: desire, erection problems in men, finishing problems in women, and overall satisfaction. The results showed improvement in sexual function and overall clinical improvement, with gender-specific improvements in erection scores in men and finishing-phase outcomes in women. There was no correlation between improvement in depression or anxiety and improvement in the sexual side effects, which is a useful detail: the sexual gain did not track with the mood gain. The caveats are the whole story, really: open-label, no placebo group, 15 completers, and the authors themselves call it preliminary. The report gives no p value, no confidence interval and no response rate. So when a forum thread says "trazodone fixed my SSRI flatness," the evidence behind that sentence is one uncontrolled study of twenty people. That counts for something. It is no verdict.

Why a sleep dose is a different question

If you were prescribed a low dose of trazodone for sleep, the numbers above are mostly not about you, and Pyke (2020) is the piece of literature that tries to make that precise. The review searched the literature on trazodone for low desire and worked out threshold doses for sedative-hypnotic effects and calculated doses for 20% occupancy of agonist receptors and 70% of antagonist receptors, across 5HT1A, 5HT2A, 5HT2C, alpha-1 and histamine type 1. Its estimated minimum effective dose for improving desire: 3.5 to 19.2 milligrams of extended-release trazodone daily, bioequivalent to 1.2 to 6.4 milligrams of immediate-release taken three times a day. The threshold dose for CNS depression sits at 75 milligrams (25 milligrams immediate-release), so the proposed desire window sits far below the sedation threshold. By receptor and pharmacokinetic data the optimal extended-release dose appears to be about 4 to 20 milligrams, though it has been tested only in much larger dose strengths; quartering options would mean 150-milligram matrix tablets down to 37.5 milligrams daily, or 50-milligram immediate-release tablets down to 12.5 milligrams two to three times daily. Every one of those figures is a calculated estimate, and no trial has tested any of them. Khouzam (2017) puts the frame around it: trazodone is an antidepressant approved for depression, and the review summarizes off-label uses including insomnia, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, eating disorders, substance use disorders, sexual side effects, certain pain conditions and rehabilitation after acute ischemic stroke, while stating that large randomized controlled trials are still needed to confirm its effects. So if you are the reader who is tired all the time, has tried everything, and wants their drive back, numbers fine, still flat is where to start.

Two questions, two piles of evidence

You are reading this because trazodone and your sex drive crossed paths. Usually the story is a low dose for sleep, and then wanting it went quiet. Sometimes it is the opposite: you read online that trazodone raises desire or fixes erection problems, and now you want to know if that is real. Both questions have been asked in trials, and the answers split into two clean piles. One pile is about how much a sleep dose costs you on desire. The other is about whether trazodone was ever shown to help erection problems at all. Each source below can answer one of those, and none of them can answer both.

What to bring to your prescriber

The fastest way to get a straight answer is to walk in with the question shaped. Bring these six things, in this order.

1. Which question you are actually asking: a sleep dose that changed your desire, or a question about desire or erections as a goal.
2. The timeline: when the change in desire started, and how long you have been on trazodone since.
3. The head-to-head result: in the 14-week trial of 195 people, trazodone showed the least desire impairment of the three drugs, 12% to 18% of men and 23% to 24% of women.
4. The meta-analysis gap: the 2009 review ranked ten drugs above placebo, and trazodone appears in neither its list nor its null list, so it simply has no data there.
5. The verdict on erection problems: the 2003 meta-analysis found no significant benefit, 37% versus 20%, and the SSRI-rescue evidence is one small open-label study. The 2020 tiny-dose idea is receptor modelling with no trial behind it.
6. If you are considering a supplement, bring the bottle in hand and ask directly.

"I've tried everything"

You have read the forums, you have waited through seasons of no interest, and you may have tried adjusting the timing of your dose, cutting back, or pushing through. That exhaustion is fair, because the honest count of what was tested is short. The erection-problem trials from the 1990s failed to show a significant benefit: one double-blind crossover in 51 men found every comparison non-significant, a 2000 trial in 34 men found no significant differences, a 1994 trial looked at a yohimbine-and-trazodone combination, and a 1996 four-arm trial left the treated groups higher than controls without significance. Then the 2003 meta-analysis pooled six of those trials across 396 men and landed on 37% versus 20% positive response, which did not reach significance. On the desire side, the whole "trazodone rescues what an SSRI took" evidence base is one small open-label study of 20 people, 15 of whom completed it, with no placebo group and no p values printed. What has never been in a trial is the stuff that usually does the work: sleep quality, the load you carry, and the state of the relationship itself. Sleep, libido and testosterone covers the first, and what HSDD actually means covers when flat desire is a pattern worth naming out loud to a clinician.

The everyday levers, and where a botanical fits

Start with who this section is not for. NUUD's own label carries a caution, and it is quoted here word for word: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. If any of those apply to you, that sentence is the answer. Talk to your prescriber first and bring the label.

A few ordinary things move desire in most people, and the free ones do more work than the internet admits.

• Sleep, in quantity and quality, since a sedating antidepressant and poor sleep feed each other. Sleep apnea and low libido covers the hidden part.
• Movement you can sustain. Exercise and libido covers the wider picture.
• Treating the depression itself, as the first lever, since the medication is doing real work and mood carries a lot of the load.
• Time and safety, with a partner or on your own, with nothing expected at the end.
• A botanical supplement, if you want one, as the smallest lever on the list.

NUUD is a botanical supplement built around desire in general. It does nothing for sleep, for depression, or for the side effects of trazodone or any antidepressant, and it has no role in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, with onset in roughly 30 to 60 minutes. If you take blood-pressure medication or have a heart, kidney or lung condition, the label says no, and your prescriber decides the rest. If your prescriber has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

Think about the prescriber who wrote your prescription. In most cases it was a sleep dose, chosen because trazodone is an antidepressant approved for depression that is widely used off-label for insomnia, and large randomized trials are still needed to confirm its effects in that use. Now put the numbers in plain words. In the one head-to-head trial of 195 people, 12% to 18% of men and 23% to 24% of women on trazodone reported desire impairment, the least of the three drugs compared, while fluoxetine came out at 43% to 51% of men. On the other pile, the 2003 meta-analysis pooled six trials in 396 men and found no significant benefit for erection problems, 37% versus 20%. Neither number points at a broken body. What flattens wanting is usually the mix: the sleep debt, the depression the medication is working on, and the life you are carrying. Those flatten desire in most people, with or without a pill in the drawer. You do not owe anyone a performance. You just want to feel normal again, to want to want it again. That is a reasonable thing to ask for, and it starts with naming it, out loud, to someone who can look at the whole picture.

Keep reading

• SSRIs and the libido drop: what helps
• Does Wellbutrin affect sex drive?
• Antidepressants and low libido
• Sleep, libido and testosterone
• Low libido in women
• Why is my libido so low?

Frequently asked questions

Does trazodone lower sex drive?
In the one head-to-head trial, yes, but less than the other two drugs. Across 195 people with major depression followed for 14 weeks, 12% to 18% of men and 23% to 24% of women on trazodone reported desire impairment, the least of the three, versus 43% to 51% of men on fluoxetine. The trial was single-blind and self-reported. The 2009 meta-analysis adds no ranking, because trazodone appears in neither its above-placebo list nor its null list, so it has no trazodone data at all.

Does trazodone increase sex drive?
There is one small signal and no confirmation. In a 2009 open-label study, 20 people on an SSRI had trazodone added for 4 weeks, 15 completed it, and results showed improvement in sexual function and overall clinical improvement. There was no placebo group and no p values printed. The 2020 review proposed tiny doses for desire, 3.5 to 19.2 milligrams of extended-release daily, but every figure there is a calculated estimate from receptor modelling, and no trial tested those doses.

Does trazodone help with erection problems?
The pooled answer is no significant benefit. The 2003 meta-analysis combined six randomized trials in 396 men and found 37% versus 20% positive response, not significant, with a 95% confidence interval from 0.8 to 3.3. The individual trials agree: the 1999 double-blind trial in 51 men found every comparison non-significant, and the 2000 trial in 34 men found no significant differences in erection duration, desire change, or morning erections.

Does a low dose of trazodone for sleep affect sex drive?
The tiny-dose range people cite, 3.5 to 19.2 milligrams of extended-release daily, comes from a 2020 review and is a receptor-modelling estimate, with no trial testing those doses. The 14-week head-to-head trial reports no drug doses, so it cannot speak to a specific sleep dose either. Insomnia is a common off-label use of trazodone, and large randomized trials are still needed to confirm its effects in that condition.

Can I take a botanical supplement with trazodone?
Ask your prescriber first, and bring the label. NUUD's label says to avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. NUUD does nothing for sleep, for depression, or for any medication's side effects, and it has no role in managing a medical condition. No interaction studies exist for this formula, so the decision is yours and your prescriber's.

References

1. Khazaie H, Rezaie L, Rezaei Payam N, Najafi F. Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial. General hospital psychiatry. 2015;37(1):40-5. https://pubmed.ncbi.nlm.nih.gov/25467077/
2. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of clinical psychopharmacology. 2009;29(3):259-66. https://pubmed.ncbi.nlm.nih.gov/19440080/
3. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU international. 2003;92(4):441-6. https://pubmed.ncbi.nlm.nih.gov/12930437/
4. Costabile RA, Spevak M. Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial. The Journal of urology. 1999;161(6):1819-22. https://pubmed.ncbi.nlm.nih.gov/10332444/
5. Enzlin P, Vanderschueren D, Bonte L, Vanderborght W, Declercq G, Demyttenaere K. Trazodone: a double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings. International journal of impotence research. 2000;12(4):223-8. https://pubmed.ncbi.nlm.nih.gov/11079363/
6. Montorsi F, Strambi LF, Guazzoni G, Galli L, Barbieri L, Rigatti P, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology. 1994;44(5):732-6. https://pubmed.ncbi.nlm.nih.gov/7974947/
7. Aydin S, Odabaş O, Ercan M, Kara H, Ağargün MY. Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British journal of urology. 1996;77(2):256-60. https://pubmed.ncbi.nlm.nih.gov/8800895/
8. Stryjer R, Spivak B, Strous RD, Shiloh R, Harary E, Polak L, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clinical neuropharmacology. 2009;32(2):82-4. https://pubmed.ncbi.nlm.nih.gov/18978492/
9. Pyke RE. Trazodone in Sexual Medicine: Underused and Overdosed? Sexual medicine reviews. 2020;8(2):206-216. https://pubmed.ncbi.nlm.nih.gov/30342856/
10. Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgraduate medicine. 2017;129(1):140-148. https://pubmed.ncbi.nlm.nih.gov/27744763/

This article is for general education and is not medical advice. Insomnia and depression are medical conditions that only a licensed clinician can diagnose and manage, and trazodone is a prescription medicine. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing insomnia, depression, the side effects of any medication, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change your medication without your doctor.